Diffuse large B-cell lymphoma
S Li, KH Young, LJ Medeiros - Pathology, 2018 - Elsevier
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …
worldwide, representing approximately 30–40% of all cases in different geographic regions …
Toward a new molecular taxonomy of diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) represents a grouping of clinically and biologically
heterogeneous tumors. Application of advanced molecular technology has significantly …
heterogeneous tumors. Application of advanced molecular technology has significantly …
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene …
Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab …
ZY Xu-Monette, L Wu, C Visco, YC Tai… - Blood, The Journal …, 2012 - ashpublications.org
TP53 mutation is an independent marker of poor prognosis in patients with diffuse large B-
cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine …
cell lymphoma (DLBCL) treated with cyclophosphamide, hydroxydaunorubicin, vincristine …
AP-1 imprints a reversible transcriptional programme of senescent cells
RI Martínez-Zamudio, PF Roux, JANLF de Freitas… - Nature cell …, 2020 - nature.com
Senescent cells affect many physiological and pathophysiological processes. While select
genetic and epigenetic elements for senescence induction have been identified, the …
genetic and epigenetic elements for senescence induction have been identified, the …
Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
E Chigrinova, A Rinaldi, I Kwee, D Rossi… - Blood, The Journal …, 2013 - ashpublications.org
Richter syndrome (RS) occurs in up to 15% of patients with chronic lymphocytic leukemia
(CLL). Although RS, usually represented by the histologic transformation to a diffuse large B …
(CLL). Although RS, usually represented by the histologic transformation to a diffuse large B …
Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell …
Background Diffuse large B-cell lymphoma (DLBCL) is an aggressive and complex disease
characterized by wide clinical, phenotypic and molecular heterogeneities. The expression …
characterized by wide clinical, phenotypic and molecular heterogeneities. The expression …
Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL
ZY Xu-Monette, M Xiao, Q Au, R Padmanabhan… - Cancer immunology …, 2019 - AACR
Abstract PD-1/L1 and CTLA-4 blockade immunotherapies have been approved for 13 types
of cancers and are being studied in diffuse large B-cell lymphoma (DLBCL), the most …
of cancers and are being studied in diffuse large B-cell lymphoma (DLBCL), the most …
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the …
S Hu, ZY Xu-Monette… - Blood, The Journal …, 2013 - ashpublications.org
CD30, originally identified as a cell-surface marker of Reed-Sternberg and Hodgkin cells of
classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma …
classical Hodgkin lymphoma, is also expressed by several types of non-Hodgkin lymphoma …
Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial
M Wang, N Fowler, N Wagner-Bartak, L Feng… - Leukemia, 2013 - nature.com
Lenalidomide–rituximab therapy is effective in grade 1–2 follicular and mantle cell
lymphoma, but its efficacy in diffuse large B-cell lymphoma (DLBCL), transformed large cell …
lymphoma, but its efficacy in diffuse large B-cell lymphoma (DLBCL), transformed large cell …